Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SBP-9330 in Healthy Volunteers and Smokers
NCT04948827Phase 1Completed
- Sponsor
- Camino Pharma
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SBP-9330 in Tobacco Use Disorder (TUD) (13 arms), sponsored by Camino Pharma. Primary endpoint: Treatment-Emergent Adverse Events at 21 days. Started Jul 2021; status: completed.
02
Drugs
SBP-9330
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04948827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948827.